Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1962 1
1972 1
1978 1
1979 2
1980 1
1981 1
1982 1
1984 1
1986 1
1988 2
1991 1
1992 1
1993 2
1994 2
1996 1
1997 4
1999 2
2000 4
2001 4
2002 5
2003 6
2004 5
2005 4
2006 5
2007 3
2008 6
2009 9
2010 8
2011 12
2012 11
2013 14
2014 13
2015 12
2016 9
2017 21
2018 16
2019 20
2020 15
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 21307846

195 results
Results by year
Filters applied: . Clear all
Page 1
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JE, Zuardi AW, Crippa JA. Bergamaschi MM, et al. Neuropsychopharmacology. 2011 May;36(6):1219-26. doi: 10.1038/npp.2011.6. Epub 2011 Feb 9. Neuropsychopharmacology. 2011. PMID: 21307846 Free PMC article. Clinical Trial.
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE. Crippa JA, et al. J Psychopharmacol. 2011 Jan;25(1):121-30. doi: 10.1177/0269881110379283. Epub 2010 Sep 9. J Psychopharmacol. 2011. PMID: 20829306 Clinical Trial.
Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
de Faria SM, de Morais Fabrício D, Tumas V, Castro PC, Ponti MA, Hallak JE, Zuardi AW, Crippa JAS, Chagas MHN. de Faria SM, et al. J Psychopharmacol. 2020 Feb;34(2):189-196. doi: 10.1177/0269881119895536. Epub 2020 Jan 7. J Psychopharmacol. 2020. PMID: 31909680
Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.
van der Flier FE, Kwee CMB, Cath DC, Batelaan NM, Groenink L, Duits P, van der Veen DC, van Balkom AJLM, Baas JMP. van der Flier FE, et al. BMC Psychiatry. 2019 Feb 13;19(1):69. doi: 10.1186/s12888-019-2022-x. BMC Psychiatry. 2019. PMID: 30760241 Free PMC article. Clinical Trial.
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW. Hofmann SG, et al. Arch Gen Psychiatry. 2006 Mar;63(3):298-304. doi: 10.1001/archpsyc.63.3.298. Arch Gen Psychiatry. 2006. PMID: 16520435 Clinical Trial.
Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder.
De Candia MP, Di Sciascio G, Durbano F, Mencacci C, Rubiera M, Aguglia E, Garavini A, Bersani G, Di Sotto A, Placidi G, Cesana BM. De Candia MP, et al. Clin Ther. 2009 Dec;31(12):2851-9. doi: 10.1016/j.clinthera.2009.12.010. Clin Ther. 2009. PMID: 20110024 Clinical Trial.
195 results
Jump to page
Feedback